Purpose: To describe the implementation and impact of integrating a clinical pharmacist into interdisciplinary Acute Care for Elderly (ACE) rounds at a teaching hospital. Methods: Pre-and postanalyses were performed 6 months before and 12 months after the intervention. We report the total number, type, and frequency of recommendations made by the clinical pharmacist, the acceptance rate by the physician, and interventions on potentially inappropriate medications (PIM). Results: Among the 588 patients who met the ACE inclusion criteria, mean age was 81.2 years, 54.9% were female, and 79.8% were of white race. A total of 1243 pharmacy recommendations were recorded. The median number of recommendations per patient increased from a median of 1 (range: 1-7) in the preintervention to 2 (1-13) in the postintervention period, resulting in an incidence rate ratio of 1.25 (95% confidence interval [CI]: 1.10-1.40). The main categories of recommendations were dose adjustment, avoidance of inappropriate therapy, and prevention of adverse drug events. In the postintervention period, there was an increase in recommendations among analgesics (from 3.7% to 7.5%), PIMs (from 12% to 14%), and, in particular, antidepressant/antipsychotics (from 1.9% to 6.0%). The acceptance rate of the recommendations remained roughly the same (86.5% vs 84.4%). Conclusion: Proactive involvement of a clinical pharmacist in ACE rounds resulted in a substantial increase in recommendation for medication changes, most notably for PIMs. These recommendations generally were accepted by physicians. The integration of a clinical pharmacist requires significant dedicated time but leads to increased recognition of drug-related problems in the acutecare setting, resulting in improved patient outcomes.
Background
In 2012, there were nearly 13 million hospital stays among adults aged 65 and older. These hospitalizations accounted for more than one-third of all US admissions and about 41.7% ($157.7 billion) of total hospital costs. 1 While hospitalization can be necessary, the elderly individuals often experience adverse outcomes such as functional decline, delirium, falls, and other iatrogenic events. [2] [3] [4] [5] One approach to preventing these "hazards of hospitalization" is to designate dedicated elder care units that incorporate geriatrics principles into care. The Acute Care for Elderly (ACE) unit is an evidence-based model of care which employs an interdisciplinary team that includes a geriatrician, a pharmacist, nursing staff, and other professionals as needed. [6] [7] [8] [9] Three meta-analyses of 19 studies and nearly 7000 patients reported that compared to standard care, patients in ACE units had less functional decline, fewer episodes of delirium and falls, and they also had shorter hospital stays and lower costs. [9] [10] [11] Polypharmacy is a major challenge for the elderly individuals; 40% of adults 65 years or older take 5 to 9 medications and 18% take 10 or more on a daily basis. 12, 13 As a consequence of age-related pharmacokinetic and pharmacodynamic changes, older adults are highly susceptible to drugdrug interactions and drug-related adverse events. Inappropriate prescribing and suboptimal medication reconciliation contribute to increasing morbidity, mortality, and health-care utilization in older adults. 14 Compared to younger adults, the elderly individuals are twice as likely to experience adverse drug reactions, and the majority of patients presenting to the emergency department (ED) with adverse drug events are seniors. 2, 15 Over the last few years, the role of pharmacists in clinical care setting has expanded nationally, with the introduction of clinical pharmacists who are directly involved in patient care. 16 Clinical pharmacists now lead many clinical services such as antimicrobial stewardship, anticoagulation monitoring, and medication reconciliation program to name a few. The hospital-based clinical pharmacists work with other healthcare professionals to ensure that the medications prescribed contribute to the best possible health outcomes. Studies from inpatient settings suggest that including pharmacists in healthcare teams prevents medication errors, adverse drug events, and improves adherence to clinical practice guidelines. 12, 17 However, the few studies, which have described the impact of a clinical pharmacist on the care of the elderly individuals were not from the United States, [18] [19] [20] did not report on the patients in ACE units or were relatively small. 21, 22 In this article, we report the number and type of pharmacy recommendations from a quality improvement intervention, which integrated a clinical pharmacist into an ACE pilot program on a medical unit. We compared the results of the first year of the ACE program with the 6 months prior to the start of the pilot. We hypothesized that active evaluation and engagement of a clinical pharmacist would increase the number of pharmacy recommendations made and that the largest increase would be in the potentially inappropriate medications (PIMs) for the elderly category.
Methods

Project Design and Patient Eligibility
This was a repeated cross-sectional quality improvement project conducted at Baystate Medical Center, a 715-bed tertiary care center in Springfield, Massachusetts. The ACE interprofessional team intervention was initiated in September 2014. Standard "ACE" eligibility criteria were used. We included adults >70 years old admitted directly from the ED to the medical unit housing our pilot program. 9 We did not include "observation" patients, since much of the published data excluded them. Since the primary goal of ACE programs is to maintain function, patients with end-stage dementia, on hospice, and those imminently dying were excluded. Patients transferred from other hospital units (because their outcomes are influenced by prior care) were also excluded. In addition, we excluded data from patients admitted in the month of September 2014, since ACE model was initiated at the end of the month.
We evaluated the time periods pre (March 1, 2014 to August 31, 2014) and post (October 1, 2014 to September 30, 2015) launch of the ACE interprofessional team with an integrated clinical pharmacist.
Description of the ACE Program
In September 2014, the Baystate Medical Center leadership approved the implementation of an ACE pilot program on 1 general medical floor. The main goals of the ACE program were prevention and early detection of delirium, avoiding functional decline, decreasing falls, and shortening length of stay. Our interprofessional team included a geriatrician or geriatrics physician assistant, pharmacist, nursing staff, case manager, volunteers, and chaplain. The team met daily Monday through Friday for 1 hour and reviewed each patient's history, care plan, and management. During the study period (which was the pilot period for 1 year), the clinical pharmacist was present consistently Monday, Wednesday, and Friday (3 days a week). There were usually about 8 patients enrolled in the pilot program at any given time. The ACE program had multiple components including staff development, delirium screening, ambulation initiatives, and advance care planning. This article reports exclusively on pharmacy interventions.
Clinical Pharmacist Integration
In the 6 months prior to the start of the program (pre-ACE period), the Pharmacy Department provided "usual care" through a hospital-wide process of medication review; if errors were found, the pharmacists then contacted the primary teams. The pharmacists did not have dedicated time to review patients' histories, and there was no specific goal of optimizing prescribing for older adults. Four clinical pharmacists on the general medicine pharmacy team rotated through this assignment. The lead pharmacist was Post Graduate Year (PGY) 1 residency trained and attained her Board Certification in Geriatric Pharmacy while the pilot was running. Two other pharmacists were also PGY1 residency trained. Since this ACE unit was part of the general medicine pharmacy care team, all clinical pharmacists rotating through this assignment received onthe-job training as required by the pharmacy department. The pharmacists were also provided with education about the ACE project emphasizing the importance of a thorough medication review and targeting recommendations to specifically address the needs and vulnerabilities of older adults. The 2012 PIMs criteria in the Beer's list (at the time of the initiation of this program, the 2015 update of the guidelines was not available) as well as other medications which may increase the risk of delirium were reviewed. 23 The process for making medication recommendations was as follows. Each morning, the unit nurse manager e-mailed the list of ACE patients to all team members. Prior to rounds, the clinical pharmacist performed a complete patient profile and comprehensive medication review including but not limited to monitoring for adverse drug reactions, renal adjustment of medications, identifying high-risk medications such as anticoagulants, and overall medication reconciliation. In addition, the pharmacist identified medications that could increase the risk of falls, PIMs for the elderly individuals. These recommendations were discussed during ACE rounds with the geriatrics clinician and recorded on a recommendation form; this form was presented for review to the primary medical team during their regular bedside rounds which included the hospitalist, house staff, nursing team, and case managers. If the primary medical team did not accept a recommendation made by the ACE team and the geriatrics team considered it important, the same recommendation was sent again the following day, and one of the geriatrics team members contacted the primary team to facilitate full discussion and reach consensus.
Data Collection
All medication recommendations made by the pharmacist (in the pre and post period) were documented by the clinical pharmacist in the electronic medical record with a standardized pharmacy form that noted the categories of the recommendations. Before the end of the shift or by the following morning, the clinical pharmacist checked the patients' profiles to determine whether the recommendations made during rounds were accepted and included this information in the pharmacy elec- 
Recommendation Types
The clinical pharmacy recommendations were made if there were any circumstances involving drug therapy that could interfere with desired health outcomes; they were classified into 5 predefined categories: (1) adverse drug event prevention;
(2) avoidance of inappropriate therapy; (3) dose adjustments; (4) new therapy recommendations; and (5) clarification of a drug order (including allergies; Table 1 )
Drug Classifications Among Recommendations
The top 20 medications were classified in the following pharmacological categories: anticholinergic, anticoagulant, antidepressant, antimicrobial, antipsychotic, nonopioid pain reliever, and opioid. These frequently prescribed classes are associated with falls or known to precipitate delirium (Supplemental Table 1 ). We also created a separate category for PIMs. A drug was classified as a PIM if it was included in Table 2 of the 2015 Updated Beers Criteria by the American Geriatric Society. 24 
Study Outcomes
The outcomes were assessed both at the patient level and at the recommendation level and included the number of recommendations suggested and the number of recommendations accepted by time period. Patient-level estimates reflect 
Data Analysis
Patient characteristics were analyzed pre and post-ACE using means and standard deviations for normally distributed continuous data, medians and ranges for skewed continuous data, and frequencies and percentages for categorical data. Study outcomes were analyzed at both the patient level and the recommendation level. All estimates and 95% confidence intervals for study outcomes pre and post-ACE team with clinical pharmacist integration were generated using Poisson regression with robust standard errors along with the marginscommand using Stata v14.2 (StataCorp, LP College Station, Texas). The Institutional Review Board of Baystate Medical Center determined that this study fulfills the requirements to be designated as a quality improvement project and not research.
Results
Patient Characteristics
Overall, 588 patients meeting the ACE eligibility criteria were hospitalized on the general medicine floor: 155 in the 6 months preintervention (25.8 per month) and 433 in the 12 months postintervention period (36.1 patients per month). The mean age of the patients was 81.2 years (standard deviation: 7.2), 45.1% were male, and 79.8% were of white race. (Table 2) Characteristics were not meaningfully different across periods.
Patient-Level Estimates
A total of 1198 pharmacy recommendations were recorded, an overall median of 2 (range: 1-13) per patient. There was an increase from a median of 1 (range: 1-7) preintervention to 2 (range: 1-13) in the postintervention period. Estimates from Poisson model suggested an absolute increase of 43 recommendations per 100 patients during the pilot period and an incident rate ratio (IRR) of 1.25 (95% confidence interval [CI]: 1.11-1.41; Table 3 and Figure 1 ). In addition to an increase in recommendations, we also observed an absolute increase in the number of recommendations accepted of 33 per 100 patients during the postperiod with an IRR of 1.22 (95% CI: 1.07-1.40).
Intervention-Level Estimates
The most frequent recommendation types were for dose adjustment (43.8% pre vs 39.1% post) and avoidance of inappropriate therapy (7.9% in both periods; Table 4 ). The largest increase in recommendations came from new therapy initiation (eg, bowel regimen for patients on narcotics) with a 3% increase and restarting home medications from 0% to 3.4% of all recommendations in the postperiod.
The overall acceptance rate for all pharmacy recommendations remained similar in both time periods (87% pre vs 85% post; IRR 0.98: 95% CI: 0.93-1.03; Table 4 ). Acceptance rates dropped for Adverse Drug Event (ADE) prevention (À7.5%) and dose adjustment (À6.5%); however, they increased (2.1%) for avoidance of inappropriate therapy. Although the acceptance rate for new therapy recommendations appears to have decreased from 100% to 85.7%, recommendations increased substantially in the postperiod (4 vs 42) generating a more stable estimate. In addition, 75% of recommendations for restarting home medications were accepted in the postperiod when compared to no recommendations prior to the clinical pharmacy intervention.
In regard to drug classifications, the most frequent recommendations were for antimicrobials (43.4% pre vs 35.4% post) and PIMs (10.5% pre vs 13.2% post; Table 5 and Figure 2 ). We observed an increase in recommendations for all drug classes ranging from 1.2% (opioids) to 2.7% (PIMs) with the exception of anticoagulants (À0.6%) and antimicrobials (À8.0%). Importantly, the frequency of recommendations increased among anticholinergics (previously nonexistent) as well as antidepressants, antipsychotics, and nonopioid pain relievers (previously <1.5%).
Acceptance rates for drug classes increased for anticoagulants (15.6%) and opioids (2.9%); however, rates dropped for antimicrobials (À3.1%; Table 5 ). In the preintervention period, the percentage of accepted recommendation was 82.1% while in the postintervention period it dropped to 70.7%. However, it should be noted that the percentage of recommendations made in the postintervention period was 2.7% more than in the preintervention period. Among the low-frequency classes in the preperiod (anticholinergics, antidepressants, antipsychotics, and nonopioid pain relievers) acceptance was lowest among antipsychotics (46.2%) and highest among the nonopioid pain relievers (90.6%).
We have also examined length of stay and 30-day readmission rates during the period of the reporting for the ACE cohort and a control group of patients with similar characteristics hospitalized during the same period of time. The average length of stay was 4.7 days in the ACE group and 5.4 days in the control; 30-day readmission rate was 15.5% and 16.4%, respectively.
Discussion
In this study, we describe the integration of a clinical pharmacist into a geriatrics multidisciplinary team in an ACE program and the impact on the number and type of drug recommendations made as well as acceptance rates. The clinical pharmacist focused on each patient's clinical details, providing individualized recommendations. This was a far more intensive scrutiny than the standard pharmacy practice which was added to the prior facility-wide monitoring. We found that overall the number of pharmacy recommendations per 100 patients increased by 25% in the postimplementation period. Compared to a prior period when the pharmacist did not have dedicated time to perform medication profile review and interact with the geriatric team, in the postintervention period, there was an increase in the recommendations made regarding pain medications, PIMs such as anticholinergics, antidepressants, and antipsychotics. Furthermore, recommendations to begin new therapies increased dramatically, and the pharmacists began recommending resumption of home medications. The majority of these recommendations were accepted by the primary health-care team, with acceptance rates for many drug categories increasing or the absolute number of accepted recommendation becoming higher in the postimplementation period. We chose to track opioid prescriptions as a separate category in addition to the Beers' PIMs. The decision about when and how to initiate opioid therapy in hospitalized elderly patients is complex. In the hospital setting, older patients may well require opiates for acute pain, but careful attention to dosing, duration of treatment, and attentive monitoring for adverse events such as constipation, sedation and falls, delirium, and urinary retention is critical, especially if the patient is taking other medications impacting the central nervous system. Thus, we felt careful attention to monitoring and balancing risks and benefits was important for these patients. We frequently suggested a nonopioid alternative such as acetaminophen and sought to use the lowest opioid dose which provided effective analgesia. If a nonopioid agent was recommended in place of an opioid, that recommendation would be labeled as "new therapy recommendation."
The role of the clinical pharmacist is to engage directly with clinical decision-making process and interact regularly with other health-care professionals, thereby contributing to quality and safety by optimizing rational drug therapy. Clinical pharmacists can make critical contributions to interprofessional teams to improve outcomes for acute care patients. This is particularly true for hospitalized older adults who are at increased risk of adverse drug events due to multiple comorbidities, complex regimes, altered pharmacokinetics and pharmacodynamics, and the prevalence of inappropriate prescribing. 25, 26 Upon completion of the first year, the clinical pharmacist attended rounds 5 days a week with the ACE team.
Although only a few studies have evaluated the integration of a clinical pharmacist into a geriatrics interprofessional team, several studies have described the beneficial impact provided by pharmacists caring for elderly adults in other settings. One study of geriatric outpatients receiving a pharmacist medication consult found that adverse drug reactions decreased at 2 months compared to baseline. 27 The Fleetwood model also showed that the majority of interventions made on nursing home residents were performed by the clinical pharmacist. 28 Al-Rashed et al evaluated medication counseling with medication cards on a geriatric unit and observed improved compliance with medications, fewer unplanned visits to a general practitioner, and fewer hospital readmissions in the group provided counseling. 29 In another study, Steurbaut et al found that pharmacists who took medication histories of patients older than 65 years identified 33% more medications than physicians and at least 1 discrepancy in the physician-acquired medication history in 60% of patients. 30 In an acute-care geriatric unit with 20 beds, the addition of a clinical pharmacist resulted in 76 interventions in a 3-month period. Interventions included drug selection, dosing, changes in therapy, medication reconciliation, and patient education. 12 Similar to other studies, we observed that in the post-ACE period, there were more pharmacy recommendations regarding pain medications, anticholinergics, antidepressants, and antipsychotics. These drug classes had generally received limited attention from pharmacy staff prior to this quality improvement intervention. Pharmacist-initiated changes attempted to decrease adverse side effects and improve patient outcomes by eliminating unnecessary medications, reducing drug-drug interactions, correcting dosing in accordance with patient renal function, and managing pain more effectively.
The acceptance rate of pharmacist recommendations by the health-care team in our study was nearly 87% in the preintervention and 85% in postintervention period which is within the range reported from other studies (85%-99%). 31 The high acceptance rate suggests that pharmacists are trusted by other clinicians to make appropriate decisions regarding drug therapy. The rate of acceptance for medications included in the PIMs category decreased by 11.4% in the postintervention period; this might reflect differing attitudes of new hospitalists, some "recommendation fatigue" or competing demands on the medical teams' attention and time. Despite this decline in acceptance rate, the absolute number of accepted recommendations on PIMs clearly rose in the intervention period. There were 23 of 28 PIMs recommendations accepted in the 6-month pre-ACE period and 87 of 123 PIMs recommendations accepted in the 1-year pilot.
Our study has several limitations. First, it represents the results of an ACE program in a single center raising issues of generalizability. However, our hospital serves as a tertiary care, community, and teaching hospital and has a diverse patient population. Second, this was a pilot intervention which we recently expanded to a larger unit. This single-unit pilot intervention was critical to secure support and demonstrate value for this quality improvement work. The clinical pharmacist is now a consistent and highly valued member of the interprofessional geriatrics team 5 days a week; the project has also paved the way for plans to increase pharmacy support as the project expands to a full unit. Third, measuring the pharmacistgenerated number of recommendations is an indirect measure of the impact on the quality of care provided. Direct analysis of adverse drug event rates before and after the intervention would allow a richer analysis of the impact. Finally, since the ACE team was not the primary team for the patients, we recognize that the primary team was in charge of making the final clinical decision, and we did not have full ownership of the patients' medical care.
Our study adds to the literature clearly describing the pharmacy component of the ACE unit and the nature of the recommendations. Further work should better quantify the impact of the intervention on the prescribing appropriateness or adverse drug reactions and other patient outcomes.
Conclusions
We found that proactive involvement of a clinical pharmacist in ACE rounds, consistently 3 times a week, resulted in a substantial increase in the recommendations for medication
